ALPHA TEKNOVA, INC. Research and Development Expense
ALPHA TEKNOVA, INC. (TKNO) reported Research and Development Expense of $554.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ALPHA TEKNOVA, INC. research and development expense for the quarter ending 2026-06-30 was $554.00K, a 4.65% decline year-over-year.
- ALPHA TEKNOVA, INC. research and development expense for the quarter ending 2026-03-31 was $609.00K, a 10.33% increase year-over-year.
- ALPHA TEKNOVA, INC. research and development expense for the quarter ending 2025-12-31 was $522.00K, a 12.12% decline year-over-year.
- ALPHA TEKNOVA, INC. research and development expense for the quarter ending 2025-09-30 was $542.00K, a 13.56% decline year-over-year.
- ALPHA TEKNOVA, INC. research and development expense for fiscal 2025 was $2.20M, a 20.37% decline from fiscal 2024.
- ALPHA TEKNOVA, INC. research and development expense for fiscal 2024 was $2.76M, a 50.44% decline from fiscal 2023.
- ALPHA TEKNOVA, INC. research and development expense for fiscal 2023 was $5.57M, a 28.05% decline from fiscal 2022.
- ALPHA TEKNOVA, INC. research and development expense for fiscal 2022 was $7.74M, a 79.43% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $554.00K 10-Q · filed 2026-08-06 | $1.16M 10-Q · filed 2026-08-06 | $1.69M derived: sum of 3 quarters · filed 2026-08-06 | $2.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $609.00K 10-Q · filed 2026-05-07 | $1.13M derived: sum of 2 quarters · filed 2026-05-07 | $1.67M derived: sum of 3 quarters · filed 2026-05-07 | $2.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.06M derived: sum of 2 quarters · filed 2026-03-02 | $1.65M derived: sum of 3 quarters · filed 2026-08-06 | $2.20M 10-K · filed 2026-03-02 |
| 2025-09-30 | $542.00K 10-Q · filed 2025-11-07 | $1.12M derived: sum of 2 quarters · filed 2026-08-06 | $1.68M 10-Q · filed 2025-11-07 | $2.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $581.00K 10-Q · filed 2026-08-06 | $1.13M 10-Q · filed 2026-08-06 | $1.73M derived: sum of 3 quarters · filed 2026-08-06 | $2.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $552.00K 10-Q · filed 2026-05-07 | $1.15M derived: sum of 2 quarters · filed 2026-05-07 | $1.77M derived: sum of 3 quarters · filed 2026-05-07 | $2.45M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.22M derived: sum of 2 quarters · filed 2026-03-02 | $1.90M derived: sum of 3 quarters · filed 2026-03-02 | $2.76M 10-K · filed 2026-03-02 |
| 2024-09-30 | $627.00K 10-Q · filed 2025-11-07 | $1.30M derived: sum of 2 quarters · filed 2025-11-07 | $2.17M 10-Q · filed 2025-11-07 | $3.48M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $678.00K 10-Q · filed 2025-08-08 | $1.54M 10-Q · filed 2025-08-08 | $2.85M derived: sum of 3 quarters · filed 2025-08-08 | $4.25M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $860.00K 10-Q · filed 2025-05-09 | $2.17M derived: sum of 2 quarters · filed 2025-05-09 | $3.57M derived: sum of 3 quarters · filed 2025-05-09 | $5.03M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.71M derived: sum of 2 quarters · filed 2025-03-07 | $4.17M derived: sum of 3 quarters · filed 2025-03-07 | $5.57M 10-K · filed 2025-03-07 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-08 | $2.86M derived: sum of 2 quarters · filed 2024-11-08 | $4.26M 10-Q · filed 2024-11-08 | $6.13M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.46M 10-Q · filed 2024-08-13 | $2.86M 10-Q · filed 2024-08-13 | $4.73M derived: sum of 3 quarters · filed 2024-08-13 | $6.65M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-13 | $3.27M derived: sum of 2 quarters · filed 2024-05-13 | $5.19M derived: sum of 3 quarters · filed 2024-05-13 | $7.12M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $3.79M derived: sum of 2 quarters · filed 2024-03-27 | $5.72M derived: sum of 3 quarters · filed 2024-03-27 | $7.74M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.93M 10-Q · filed 2023-11-13 | $3.85M derived: sum of 2 quarters · filed 2023-11-13 | $5.87M 10-Q · filed 2023-11-13 | $7.26M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.93M 10-Q · filed 2023-08-11 | $3.94M 10-Q · filed 2023-08-11 | $5.33M derived: sum of 3 quarters · filed 2023-08-11 | $6.70M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $2.01M 10-Q · filed 2023-05-11 | $3.40M derived: sum of 2 quarters · filed 2023-05-11 | $4.78M derived: sum of 3 quarters · filed 2023-05-11 | $5.63M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $2.76M derived: sum of 2 quarters · filed 2023-03-30 | $3.61M derived: sum of 3 quarters · filed 2023-03-30 | $4.31M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.37M 10-Q · filed 2022-11-14 | $2.22M derived: sum of 2 quarters · filed 2022-11-14 | $2.92M 10-Q · filed 2022-11-14 | $3.40M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $851.00K 10-Q · filed 2022-08-11 | $1.55M 10-Q · filed 2022-08-11 | $2.03M derived: sum of 3 quarters · filed 2022-08-11 | $2.39M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-12 | $1.18M derived: sum of 2 quarters · filed 2022-05-12 | $1.54M derived: sum of 3 quarters · filed 2022-05-12 | $1.88M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $840.00K derived: sum of 2 quarters · filed 2022-03-18 | $1.18M derived: sum of 3 quarters · filed 2022-03-18 | $1.51M 10-K · filed 2022-03-18 |
| 2020-09-30 | $358.00K 10-Q · filed 2021-11-12 | $699.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.02M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $341.00K 10-Q · filed 2021-08-13 | $667.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |